US90138Q1085 - Common Stock
2.08 +0.04 (+1.96%)
After market: 2.07 -0.01 (-0.48%)
23andMe press release (NASDAQ:ME): Q4 GAAP EPS of -$0.14 beats by $0.04.Revenue of $92.4M (-8.1% Y/Y) beats by $4M.
Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN...
Neither has a traditional business model, but that could be an asset for both.
New opportunities are becoming apparent, but so are fresh risks in the biotech field.
Explore the world of high-risk penny stocks, with their potential for significant returns, as we analyze three speculative opportunities.
66 percent of doctors say genetic testing could lead to better outcomes because patients are more proactive about their health after learning about their...
Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out.
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical...
23andMe+ members can now gain insights on the chronic autoimmune condition
23andMe+ members can now gain insights on the chronic autoimmune condition...
Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategy
First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with...
Program aims to increase access to information on sickle cell carrier status, and offer resources to individuals with sickle cell trait and sickle cell...
/PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company with a mission to help people access,...
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers...
Biotechs with an AI strategy are likely to be the first to flourish from the disruptions.
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented...
They've been using machine learning for years, and now they might do even more.
92 percent of doctors in the U.S. say genetics is an important part of a patient’s complete health picture66 percent of doctors say genetic testing could...
There's nothing better than getting a bargain that'll pay off for years.
Mukesh Ambani's Reliance is seeking to disrupt DNA testing with $145 genome sequencing kits — undercutting rivals charging $1,000
Both are likely to double quite soon, and they aren't even that risky.
The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profile of 23ME-00610
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical...
This healthcare company isn't without risk but is doing a good job executing on its vision.